Crescendo Bioscience, a
wholly-owned subsidiary of Myriad Genetics, Inc. MYGN, today
presented new data that showed Vectra^® DA is a better predictor of
radiographic progression over two years than other tests used to assess risk
of joint damage in rheumatoid arthritis (RA), such as C-reactive protein
(CRP). The oral presentation was featured at the 2014 American College of
Rheumatology (ACR) Annual Meeting in Boston, Massachusetts.
The study included 143 patients with RA who had received a stable treatment
and were enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential
Study (BRASS) registry in the United States. Patients were evaluated at their
initial visit in the BRASS registry for the Vectra DA score and conventional
measures of disease activity, including CRP, DAS28-CRP, CDAI, SDAI and RAPID3,
and provided X-rays of hands and wrists at approximately the initial visit and
two years later. These data were used to assess the relationship between
disease activity and the amount of subsequent new joint damage seen on X-rays
(radiographic progression).
The results showed that Vectra DA was the best independent predictor of
disease progression over two years when compared with standard measures based
on the exam or patient reported outcome. The odds ratio for predicting
progression was highest for Vectra DA and lowest for RAPID3. Importantly,
among patients with a low CRP at baseline, defined as <1 mg/dL, radiographic
progression was observed in 34.8 percent of patients with a high Vectra DA
score versus 8.1 percent of patients with a low/moderate Vectra DA score
(p=0.003), providing further evidence that Vectra DA provides information for
predicting joint damage that is not provided by CRP.
"In this study of U.S. patients, Vectra DA was a strong predictor of joint
damage over two years, compared with other tests," said Eric Sasso, M.D., vice
president of medical and scientific affairs at Crescendo Bioscience. "These
data build on prior studies demonstrating that Vectra DA can assess risk for
joint damage and complement other measures of disease activity."
Another study featured at ACR provided an analysis of radiographic progression
in patients with early RA from the Swedish Farmacotherapy (SWEFOT) clinical
trial. The Vectra DA test was used to evaluate 220 patients for progression
from baseline to Year 1 and from baseline to Year 2. In addition, progression
from Year 1 to Year 2 was evaluated for 133 patients who had inadequate
initial responses to methotrexate and were treated from month three with the
addition of a TNF inhibitor or with triple therapy using methotrexate,
sulfasalazine and hydroxychloroquine.
Among patients with a high Vectra DA score at baseline, 25 percent of those
with a high Vectra DA score at month three showed rapid radiographic
progression during the first year, and 35 percent of those with a high Vectra
DA score at one year showed rapid radiographic progression between Year 1 and
Year 2. By contrast, for patients whose high baseline Vectra DA score declined
to low after three months or one year of treatment, only 6 and 4 percent
showed rapid radiographic progression between Year 1 and Year 2. Moreover,
for patients who had a moderate Vectra DA score at baseline and achieved a low
Vectra DA score at 3 months, none showed rapid radiographic progression during
the first year.
"In this study, a high Vectra DA score was associated with markedly increased
risk for joint damage and a low Vectra DA score was associated with low risk
for subsequent joint damage," said Dr. Sasso. "These findings suggest how
Vectra DA may be used to objectively assess disease activity following
initiation of therapy to help manage the patient's disease."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in